INSIGHTS ON PHARMACEUTICAL LOGISTICS

• Manufacturing Made More Robust And Customer-Centric

  Discover how regional manufacturing, risk-aware practices, and agile strategies are reshaping supply chains to deliver resilience, transparency, and sustainability in today’s complex global environment.

• Integrated Single-Site CDMO Model

  A single‑site model reduces handoff risks, speeds timelines, strengthens quality oversight, and unifies development and manufacturing to improve reliability and execution efficiency.

• How To Select The Right Fill-Finish CDMO For Phase I–II

  Early‑phase programs require flexible, technically aligned fill‑finish partners. Mid‑sized CDMOs offer a balance of agility, infrastructure, and regulatory maturity suited to Phase I–II needs.

• From LAL To rFC: The Evolution Of Endotoxin Testing

  Protect patient safety and ensure regulatory compliance by implementing sensitive, reliable bacterial endotoxin testing as a critical component of pharmaceutical quality assurance.

• Collaborative Supply Chain Management In A Fragmented World

  6/15/2026

  Biopharma supply chains are under pressure. As regionalization accelerates, success depends on agility, trust, and new approaches to collaboration that can withstand ongoing global uncertainty.

• Site Transfer Of Tablet Production From Ex-U.S. To Georgia Site

  6/11/2025

  Explore how strategic U.S.-based manufacturing and supply chain diversification can reduce risk, lower costs, and enhance supply reliability for pharmaceutical products.

• Shedding Light On Photo-Stability Forced Degradation

  11/26/2024

  Ensure the stability and safety of your drug products by utilizing comprehensive forced degradation and photo-stability testing, guided by ICH and FDA standards, to identify degradation pathways and assess light exposure risks.

• Building A Resilient Supply Chain For Your Next-Generation Peptide Therapeutic

  1/23/2025

  As peptide therapeutics continue to establish themselves as a leading technology for treating chronic indications, drug sponsors must identify reliable peptide building block suppliers to secure high-quality starting materials.

• The Connectivity Crisis Blocking AI Deployment

  6/30/2026

  Disconnected systems and siloed data block analytics in life sciences manufacturing. Learn to bridge the infrastructure gap and build a connected foundation for scalable intelligence.